Basilea Raises 2026 Operating Profit Guidance to CHF 115 Million
Basilea expects 2026 operating profit of CHF 115 million, up from its previous forecast of CHF 70 million. It also raised its financial target for “Agenda 2030” and provided updates on late-stage clinical programs.
Story updates
06:05:25 AM UTC
SquawkNews
BASILEA PHARMACEUTICA - FY2026 R&D EXPENSES GUIDANCE CHF 125 MLN; OPERATING PROFIT GUIDANCE CHF 115